Research Institute Havelhöhe at the Hospital Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany.
Interdisciplinary Oncology and Palliative Care, Hospital Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany.
Complement Med Res. 2022;29(4):362-368. doi: 10.1159/000524184. Epub 2022 Mar 24.
A majority of oncological patients apply add-on white-berry European mistletoe (Viscum album L., VA) extracts to reduce disease- and treatment-related symptoms and to improve health-related quality of life (HRQL). VA extracts exert various antitumor, pro-apoptotic, anti-proliferative, and immunomodulatory effects. Two current meta-analyses attribute life-prolonging and HRQL-improving properties to additive VA therapy. The aim of the present update was to review the current knowledge on VA extracts in clinical oncology. Hereby, we concentrated on studies with the highest clinical relevance in the field of lung, gastric, colorectal and pancreatic, gynaecological, as well as breast cancer applying the anthroposophical mistletoe preparations.
The present update provides a brief overview regarding the use of VA preparations in clinical oncology reviewing current guidelines, systematic reviews, randomized controlled and real-world data studies. We have searched the pubmed.gov database of the National Library of Medicine with the search terms "mistletoe" and "cancer." We found good evidence of add-on VA therapy to improve the HRQL of patients with breast cancer (American Society of Clinical Oncology - endorsed Society for Integrative Oncology guideline) and of HRQL-improving and survival-prolonging properties of VA therapy in pancreatic cancer. In the field of gastrointestinal, gynaecological, and lung cancer, new or updating integrative and/or oncological guidelines should consider clear recommendations on integrative therapies including VA therapy. Nevertheless, further clinical and real-world data trials need to be performed in this field.
Evidence for add-on VA treatment for the improved management of cancer and cancer-related side effects is accumulating. Patients with breast cancer: good evidence for add-on VA therapy to improve the HRQL of oncological patients. Patients with pancreatic cancer: good evidence for add-on VA to improve HRQL and prolong survival. Patients with gastrointestinal, gynaecological, and lung cancer: update of guidelines is recommended with regards to integrative oncological therapies including add-on VA.
大多数肿瘤患者应用附加白浆果欧洲槲寄生（Viscum album L.，VA）提取物来减轻疾病和治疗相关症状，提高健康相关生活质量（HRQL）。VA 提取物具有多种抗肿瘤、促凋亡、抗增殖和免疫调节作用。目前有两项荟萃分析认为附加 VA 治疗具有延长生命和提高 HRQL 的作用。本更新旨在综述 VA 提取物在临床肿瘤学中的最新知识。在此，我们专注于在肺癌、胃癌、结直肠癌和胰腺癌、妇科以及乳腺癌领域具有最高临床相关性的研究，应用Anthroposophical 槲寄生制剂。
本更新提供了关于 VA 制剂在临床肿瘤学中的应用的简要概述，回顾了当前的指南、系统评价、随机对照和真实世界数据研究。我们在国家医学图书馆的 PubMed.gov 数据库中使用了“槲寄生”和“癌症”这两个检索词进行了搜索。我们发现了良好的证据表明附加 VA 治疗可以改善乳腺癌患者的 HRQL（美国临床肿瘤学会认可的整合肿瘤学学会指南），并且 VA 治疗在胰腺癌中具有改善 HRQL 和延长生存的作用。在胃肠道、妇科和肺癌领域，新的或更新的整合和/或肿瘤学指南应该考虑在整合治疗中包括 VA 治疗的明确建议。然而，这一领域仍需要进一步进行临床和真实世界的数据试验。
VA 治疗附加治疗癌症和癌症相关副作用的证据正在积累。乳腺癌患者：有良好的证据表明附加 VA 治疗可以改善肿瘤患者的 HRQL。胰腺癌患者：有良好的证据表明附加 VA 治疗可以改善 HRQL 并延长生存。胃肠道、妇科和肺癌患者：建议更新指南，将包括附加 VA 在内的整合肿瘤学治疗纳入其中。
